Endo Hirsutism Avoid Gnrh Agonist Except Severe

Avoid GnRH agonists except in severe hyperandrogenemia with suboptimal response to OC/antiandrogen

STEP 1 — Gather Information

Collect Ferriman–Gallwey score, serum total and free testosterone, menstrual history, duration and response to at least 6 months of oral contraceptive plus antiandrogen therapy, and assess for signs of ovarian hyperthecosis (e.g., LH/FSH ratio >2, virilization, markedly elevated androgens).
Action: Proceed to Step 2 to evaluate eligibility for GnRH agonist therapy.

STEP 2 — Rule In / Rule Out

Is there severe hyperandrogenemia (e.g., ovarian hyperthecosis) and a suboptimal response to ≥6 months of OC plus antiandrogen?

• Yes: Go to Step 3.
• No: Rule out GnRH agonist therapy; proceed to alternative management (optimize OC/antiandrogen, consider lifestyle, or direct hair removal).
  Decision: Determine whether GnRH agonist is contraindicated or may be considered.

STEP 3 — Classify or Stratify

Assess baseline bone mineral density (DXA if available) and menopausal symptom risk to determine suitability for add‑back estrogen/progestin therapy.

• Adequate bone health / low risk: Proceed to Step 4.
• Significant bone loss or high fracture risk: Consider non‑GnRH alternatives (e.g., higher‑dose antiandrogen, laser photoepilation) and avoid GnRH agonist.
  Action: Classify patient as suitable or unsuitable for GnRH agonist with add‑back.

STEP 4 — Decide

If suitable, initiate a GnRH agonist (e.g., leuprolide 3.75 mg IM monthly) combined with add‑back therapy (norethindrone 5 mg daily or a low‑dose OC containing ≤20 mcg EE) for 6 months, then reassess hirsutism score and symptoms.
If unsuitable, avoid GnRH agonist and optimize current therapy or pursue definitive hair removal modalities.
Decision: Prescribe GnRH agonist with add‑back only when strict criteria are met; otherwise, refrain from use.

Clinical Guardrails / Mimics / Pitfalls

• GnRH agonists cause profound hypoestrogenism, leading to menopausal symptoms and bone loss; add‑back estrogen/progestin is mandatory to mitigate these effects.
• Therapy is expensive, requires intramuscular or subcutaneous injections, and demands frequent monitoring.
• Do not use GnRH agonists as first‑line or for mild/moderate hirsutism; reserve for refractory, severe hyperandrogenemia only.
• Monitor lumbar spine and hip BMD every 6–12 months if therapy exceeds 6 months.
• Watch for persistent vasomotor symptoms; adjust add‑back dose if needed.
• Avoid in patients with uncontrolled osteoporosis, active thromboembolic disease, or pregnancy.

Concrete Clinical Example

A 30‑year‑woman presents with Ferriman–Gallwey 24, total testosterone 85 ng/dL, and reports minimal improvement after 8 months of OC (EE 30 mcg + levonorgestrel) plus spironolactone 200 mg daily. Labs show LH/FSH ratio 2.5 and elevated DHEAS, suggesting ovarian hyperthecosis. Bone density is normal. She meets criteria for severe hyperandrogenemia with suboptimal OC/antiandrogen response; GnRH agonist leuprolide 3.75 mg monthly plus norethindrone 5 mg daily is initiated. After 6 months, her FG score drops to 12 and she reports satisfactory hair growth control.

Source: Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-00241